|
1
|
Bo K, Frawley HC, Haylen BT, Abramov Y,
Almeida FG, Berghmans B, Bortolini M, Dumoulin C, Gomes M, McClurg
D, et al: An International Urogynecological Association
(IUGA)/International Continence Society (ICS) joint report on the
terminology for the conservative and nonpharmacological management
of female pelvic floor dysfunction. Neurourol Urodyn. 36:221–244.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Scarneciu I, Lupu S, Bratu OG, Teodorescu
A, Maxim LS, Brinza A, Laculiceanu AG, Rotaru RM, Lupu AM and
Scarneciu CC: Overactive bladder: A review and update. Exp Ther
Med. 22(1444)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Eapen RS and Radomski SB: Review of the
epidemiology of overactive bladder. Res Rep Urol. 8:71–76.
2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sumardi R, Mochtar CA, Junizaf Santoso BI,
Setiati S, Nuhonni SA, Trihono PP, Rahardjo HE and Syahputra FA:
Prevalence of urinary incontinence, risk factors and its impact:
Multivariate analysis from Indonesian nationwide survey. Acta Med
Indones. 46:175–182. 2014.PubMed/NCBI
|
|
5
|
Millman AL, Cheung DC, Hackett C and
Elterman D: Overactive bladder in men: A practical approach. Br J
Gen Pract. 68:298–299. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lin XD, Lin N, Ke ZB, Xu N, Jiang P and Li
H: Effects of overactive bladder syndrome on female sexual
function. Medicine (Baltimore). 100(e25761)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Edmonds VS and Khan AA: Overactive
Bladder: The Patient Perspective. Curr Bladder Dysfunct Rep.
19:89–94. 2024.
|
|
8
|
Jiang YH and Kuo HC: Current optimal
pharmacologic therapies for overactive bladder. Expert Opin
Pharmacother. 24:2005–2019. 2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kreydin EI, Gomes CM and Cruz F: Current
pharmacotherapy of overactive bladder. Int Braz J Urol.
47:1091–1107. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cameron AP, Chung DE, Dielubanza EJ,
Enemchukwu E, Ginsberg DA, Helfand BT, Linder BJ, Reynolds WS,
Rovner ES, Souter L, et al: The AUA/SUFU guideline on the diagnosis
and treatment of idiopathic overactive bladder. J Urol. 212:11–20.
2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Burgio KL, Kraus SR, Johnson TM II,
Markland AD, Vaughan CP, Li P, Redden DT and Goode PS:
Effectiveness of combined behavioural and drug therapy for
overactive bladder symptoms in men: A Randomized clinical trial.
JAMA Intern Med. 180:411–419. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
La Rosa VL, Duarte de Campos da Silva T,
Rosa de Oliveira A, Marques Cerentini T, Viana da Rosa P and Telles
da Rosa LH: Behavioural therapy versus drug therapy in individuals
with idiopathic overactive bladder: A systematic review and
meta-analysis. J Health Psychol. 25:573–585. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shapiro KK and Brucker BM: Treatment of
overactive bladder in men: Is it really different? Neurourol
Urodyn. 41:1975–1982. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372(n71)2021.PubMed/NCBI View
Article : Google Scholar
|
|
15
|
Sterne JAC, Savović J, Page MJ, Elbers RG,
Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge
SM, et al: RoB 2: a revised tool for assessing risk of bias in
randomised trials. BMJ. 366(l4898)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wells G, Shea B, O'Connel D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality of nonrandomised studies in
meta-analyses. The Ottawa Hospital Research Institute. https://ohri.ca/en/who-we-are/core-facilities-and-platforms/ottawa-methods-centre/newcastle-ottawa-scale.
Accessed April 13, 2025.
|
|
17
|
Burgio KL, Locher JL and Goode PS:
Combined behavioural and drug therapy for urge incontinence in
older women. J Am Geriatr Soc. 48:370–374. 2000.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Klutke CG, Burgio KL, Wyman JF, Guan Z,
Sun F, Berriman S and Bavendam T: Combined effects of behavioural
intervention and tolterodine in patients dissatisfied with
overactive bladder medication. J Urol. 181:2599–2607.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lin CC, Kuo HC, Li JR and Chuang YC:
Comparative study between behavior therapy and behavior therapy
plus mirabegron 50 mg in sexually active men with bothersome
overactive bladder symptoms-a multicenter, randomized study. Int
Neurourol J. 27:182–191. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bo K, Fernandes ACNL, Duarte TB, Brito LGO
and Ferreira CHJ: Is pelvic floor muscle training effective for
symptoms of overactive bladder in women? A systematic review.
Physiotherapy. 106:65–76. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Tibaek S, Gard G, Dehlendorff C, Iversen
HK, Biering-Soerensen F and Jensen R: Is pelvic floor muscle
training effective for men with poststroke lower urinary tract
symptoms? A single-blinded randomized, controlled trial. Am J Mens
Health. 11:1460–1471. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sheng Y, Carpenter JS, Ashton-Miller JA
and Miller JM: Mechanisms of pelvic floor muscle training for
managing urinary incontinence in women: A scoping review. BMC
Womens Health. 22(161)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hagovska M, Svihra J Sr, Macko L, Breza J
Jr, Svihra J Jr, Luptak J and Lachvac L: The effect of pelvic floor
muscle training in men with benign prostatic hyperplasia and
overactive bladder. World J Urol. 42(287)2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Liu P, Li Y, Shi B, Zhang Q and Guo H:
Comparison of different types of therapy for overactive bladder: A
systematic review and network meta-analysis. Front Med (Lausanne).
9(1014291)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Enemchukwu EA, Subak LL and Markland A:
Barriers and facilitators to overactive bladder therapy adherence.
Neurourol Urodyn. 41:1983–1992. 2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Carlson KV, Rovner ES, Nair KV, Deal AS,
Kristy RM and Hairston JC: Persistence with mirabegron or
antimuscarinic treatment for overactive bladder syndrome: Findings
from the PERSPECTIVE registry study. Low Urin Tract Symptoms.
13:425–434. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Duckett J and Balachandran A: Tolerability
and persistence in a large, prospective case series of women
prescribed mirabegron. Int Urogynecol J. 27:1163–1167.
2016.PubMed/NCBI View Article : Google Scholar
|
